Nothing Special   »   [go: up one dir, main page]

DE60230736D1 - HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; - Google Patents

HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;

Info

Publication number
DE60230736D1
DE60230736D1 DE60230736T DE60230736T DE60230736D1 DE 60230736 D1 DE60230736 D1 DE 60230736D1 DE 60230736 T DE60230736 T DE 60230736T DE 60230736 T DE60230736 T DE 60230736T DE 60230736 D1 DE60230736 D1 DE 60230736D1
Authority
DE
Germany
Prior art keywords
humanized antibodies
recognize
humanized
amyloid peptide
beta amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230736T
Other languages
English (en)
Inventor
Naoya Tsurushita
Maximilano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60230736D1 publication Critical patent/DE60230736D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60230736T 2001-04-30 2002-04-26 HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; Expired - Lifetime DE60230736D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28753901P 2001-04-30 2001-04-30
PCT/US2002/011853 WO2002088306A2 (en) 2001-04-30 2002-04-26 Humanized antibodies

Publications (1)

Publication Number Publication Date
DE60230736D1 true DE60230736D1 (de) 2009-02-26

Family

ID=23103359

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230736T Expired - Lifetime DE60230736D1 (de) 2001-04-30 2002-04-26 HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;

Country Status (7)

Country Link
US (1) US7318923B2 (de)
EP (2) EP1385545B1 (de)
AT (1) ATE420114T1 (de)
AU (1) AU2002258808A1 (de)
DE (1) DE60230736D1 (de)
ES (2) ES2437875T3 (de)
WO (1) WO2002088306A2 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2007231637B8 (en) * 2000-12-06 2011-12-08 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US20050129695A1 (en) * 2003-03-28 2005-06-16 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050048617A1 (en) * 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
PL1720909T3 (pl) * 2004-02-23 2012-04-30 Lilly Co Eli Przeciwciało anty-abeta
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
WO2007024249A2 (en) * 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
AR052051A1 (es) * 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006220709B2 (en) 2005-03-04 2012-09-06 Biogen Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US7825223B2 (en) 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies
JP5105485B2 (ja) * 2005-08-10 2012-12-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を有する抗体の同定および工学的改変およびその使用方法
ES2524984T3 (es) 2005-11-30 2014-12-16 Abbvie Inc. Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
IL297746A (en) 2005-11-30 2022-12-01 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
EP2377886A1 (de) 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antikörperglycosylierung in der variablen Region
RS53291B (en) * 2005-12-12 2014-08-29 Ac Immune S.A. BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES
SG170110A1 (en) * 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
PL2029173T3 (pl) * 2006-06-26 2017-04-28 Macrogenics, Inc. Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
EP1887084A1 (de) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008045563A2 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
CA2684323A1 (en) * 2007-04-18 2008-10-30 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8323654B2 (en) * 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9040045B2 (en) 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
DK2238166T3 (da) * 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN104098695B (zh) * 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
CN102046655B (zh) * 2008-04-02 2016-09-14 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
US20110081347A1 (en) * 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
JP6273214B2 (ja) * 2012-02-17 2018-01-31 シアトル ジェネティックス， インコーポレイテッド がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用
US8597647B1 (en) 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014102104A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Artificial introns
WO2014102101A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102100A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within an immunoglobulin domain
EP2938726B1 (de) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologes intron mit einem signalpeptid
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase
WO2019139987A1 (en) * 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3836966A4 (de) * 2018-08-17 2022-06-08 Ab Studio Inc. Katalytische antikörper und verfahren zur verwendung davon
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
KR20220110231A (ko) 2019-12-05 2022-08-05 씨젠 인크. 항-αvβ6 항체 및 항체-약물 접합체
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165496A (en) * 1875-07-13 Improvement in machines for cutting corn-stalks
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
ES2312185T3 (es) 1997-04-09 2009-02-16 Intellect Neurosciences, Inc. Anticuerpos recombinantes especificos contra las terminaciones de amiloide beta, adn que codifica y procedimientos de utilizacion de los mismos.
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
MXPA00011348A (es) 1998-05-21 2003-04-22 Univ Tennesse Res Corp Metodos para la remocion de material amiloide utilizando anticuerpos anti-amiloide.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
WO2001018169A2 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
SI1481992T1 (sl) * 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
EP1385545A2 (de) 2004-02-04
US7318923B2 (en) 2008-01-15
WO2002088306A3 (en) 2003-07-10
ATE420114T1 (de) 2009-01-15
EP2165714A1 (de) 2010-03-24
ES2437875T3 (es) 2014-01-14
EP2165714B1 (de) 2013-10-23
AU2002258808A1 (en) 2002-11-11
EP1385545A4 (de) 2005-10-19
ES2318006T3 (es) 2009-05-01
EP1385545B1 (de) 2009-01-07
US20050090648A1 (en) 2005-04-28
WO2002088306A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
DE60230736D1 (de) HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
EP1385544A4 (de) Humanisierte antikörper
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
ATE291086T1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IL154298A0 (en) Papap proteins, their preparation and use
WO2002081625A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
DE60125148D1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002099062A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same
WO2002090504A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002008289A3 (en) Novel proteins and nucleic acids encoding same
WO2001025436A3 (en) Endozepine-like polypeptides and polynucleotides encoding same
WO2002030974A3 (en) Proteins and nucleic acids encoding same
WO2001094416A3 (en) Human proteins and nucleic acids encoding same
WO2002050276A3 (en) Proteins and nucleic acids encoding same
WO2001074897A3 (en) Protein amf-1 to amf-10 and nucleic acids encoding the same
WO2002040539A3 (en) Gpcr-like protein and nucleic acids encoding same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN